Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 14
Phase 21

Trial Status

Completed3
Other1

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT02540876Phase 1Completed
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
Metastatic Malignant NeoplasmSolid NeoplasmUnresectable Malignant Neoplasm
PrincipalinvestigatorStart date: 2015-09-08
NCT01174264Phase 1/2Completed
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Malignant Neoplasm
Principalinvestigator
NCT02333188Phase 1Completed
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
Adenocarcinoma of Unknown PrimaryAdult CholangiocarcinomaGallbladder Carcinoma+14 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT02540876Phase 1PrincipalInvestigator

Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery

Metastatic Malignant NeoplasmSolid NeoplasmUnresectable Malignant Neoplasm
Completed
NCT01174264Phase 1/2PrincipalInvestigator

Evaluation of Food Effect on Pharmacokinetics of Vismodegib

Malignant Neoplasm
Completed
NCT02333188Phase 1PrincipalInvestigator

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

Adenocarcinoma of Unknown PrimaryAdult CholangiocarcinomaGallbladder Carcinoma+14 more
Completed
NCT02573220Phase 1PrincipalInvestigator

Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer

Stage IVA Colorectal CancerStage IVB Colorectal Cancer
Withdrawn

All 4 trials loaded